Decreasing Opioid Use Postpartum: A Quality Improvement Initiative.


Journal

Obstetrics and gynecology
ISSN: 1873-233X
Titre abrégé: Obstet Gynecol
Pays: United States
ID NLM: 0401101

Informations de publication

Date de publication:
11 2019
Historique:
pubmed: 11 10 2019
medline: 2 4 2020
entrez: 11 10 2019
Statut: ppublish

Résumé

To estimate the effects of an inpatient initiative to decrease opioid use among women admitted to labor and delivery. We created a multimodal pain power plan with standard therapeutic postpartum activity goals rather than pain goals, tiered order sets with scheduled administration of nonsteroidal antiinflammatory drugs (NSAIDs), and embedded changes into the electronic health record. Before the multimodal pain power plan launch, pain was assessed on a 10-point scale; women received NSAIDs for pain levels of 3 or less and opioids for pain levels higher than 3. For this analysis, we included women who delivered at 5 hospitals in the 10 months before and 12 months after the multimodal pain power plan launch. Women with prior substance use disorder or complicated deliveries were excluded and we stratified analyses into women who delivered vaginally compared with by cesarean. Opioid use was converted to morphine milligram equivalent (MME). Women rated pain control in 24-hour blocks using individually ascertained cutoffs. A multivariable regression analysis was performed, and adjusted odds ratios are reported. We compared the 6,892 women who delivered 10 months before the pain power plan launch to the 7,527 who delivered in the 12 months after the launch. The mean cohort age was 29.6±6.0 years; the majority (75%) were white. Risk of opioid use decreased by 26% among women who delivered vaginally (risk ratio [RR] 0.74; 95% CI [0.68, 0.81]) and 18% among women who delivered by cesarean (RR 0.82; 95% CI [0.72, 0.92]). Among women who received opioids, mean MME use decreased 21% (RR 0.79; 95% CI [0.70, 0.88]) and 54% (RR 0.46; 95% CI [0.35, 0.61]) in the vaginal and cesarean delivery groups, respectively. Fewer women reported acceptable pain levels, with decreases of 82-69% (P<.01) and 82-74% (P<.01) in the vaginal and cesarean delivery groups, respectively. Within the postlaunch cesarean delivery group, women also reported that they were less likely to have their pain well controlled on the Hospital Consumer Assessment of Healthcare Providers and Systems questionnaires (82% vs 62%, P <.01). A standardized multimodal pain power plan reduced opioid use among a large cohort of women admitted to labor and delivery in Central Texas. Despite meeting functional goals, some women reported increased pain during their hospital stay.

Identifiants

pubmed: 31599842
doi: 10.1097/AOG.0000000000003512
pii: 00006250-201911000-00006
doi:

Substances chimiques

Anti-Inflammatory Agents, Non-Steroidal 0
Morphine 76I7G6D29C

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

932-940

Références

Van Houten JP, Rudd BA, Ballesteros MF, Mack KA. Drug overdose among women ages 30–64 years. United States, 1999–2017. MMWR Morb Mortal Wkly Red 2019;68:1–5.
Bateman BT, Franklin JM, Bykov K, Avorn J, Shrank WH, Brennan TA, et al. Persistent opioid use following cesarean delivery: patterns and predictors among opioid naïve women. Am J Obstet Gynecol 2016;215:353.e1–18.
Deyo RA, Hallvik SA, Hildebran C, Marino M, Dexter E, Irvine JM, et al. Association between initial opioid prescribing patterns and subsequent long-term use among opioid-naïve patients: a statewide retrospective cohort study. J Gen Intern Med 2017;32:21–37.
Osmundson SS, Wiese AD, Min JY, Hawley RE, Patrick SW, Griffin MR, et al. Delivery type, opioid prescribing, and the risk of persistent opioid use after delivery. Am J Obstet Gynecol 2018;220:405–7.
Osmundson SS, Schomack LA, Grasch JL, Zuckerwise LC, Young JL, Richardson MG. Postdischarge opioid use after cesarean delivery. Obstet Gynecol 2017;130:36–41.
Prabhu M, Garry EM, Hernandez-Diaz S, MacDonald SC, Huybrechts KF, Bateman BT. Frequency of opioid dispensing after vaginal delivery. Obstet Gynecol 2018;132:459–65.
Badreldinet N, Grobman WA, Chang KT, Yee LM. Patient and health care provider factors associated with prescription of opioids after delivery. Obstet Gynecol 2018;132:929–36.
Mills JR, Huizinga MM, Robinson SB, Lamprecht L, Handler A, Petros M, et al. Draft opioid-prescribing guidelines for uncomplicated normal spontaneous vaginal birth. Obstet Gynecol 2019;133:81–90.
America's Health Rankings, United Health Foundation. Maternal mortality in Texas. Available at: https://www.americashealthrankings.org/explore/health-of-women-and-children/measure/maternal_mortality/state/TX 3.18.19. Retrieved March 18, 2019.
Dieterichs C, Davis JD, Uhler L, Vetter TR. The therapeutic activity goal for acute postoperative pain management: a case report. A A Pract 2018;10:157–9.
McPherson ML. Demystifying opioid conversion calculations: a guide for effective dosing. Bethesda, MD: American Society of Health-Systems Pharmacists; 2010.
Long JS, Ervin LH. Using heteroscedasticity consistent standard errors in the linear regression model. Am Stat 2000;54:217–24.
Holland I, Bateman BT, Cole N, Taggart A, Robinson LA, Sugrue R, et al. Evaluation of a quality improvement intervention that eliminated routine opioids after cesarean delivery. Obstet Gynecol 2018;133:91–7.
Becker NV, Gibbins KJ, Perrone J, Maughan BC. Geographic variation in postpartum prescription opioid use: opportunities to improve maternal safety. Drug Alcohol Depend 2018;188:288–94.
Yajnik M, Hill JN, Hunter OO, Howard SK, Kim TE, Harrison TK, et al. Patient education and engagement in postoperative pain management decreases opioid use following knee replacement surgery. Patient Educ Couns 2019;102:383–7.

Auteurs

Rebecca G Rogers (RG)

Departments of Women's Health, Surgery and Perioperative Care, and Population Health, Dell Medical School, University of Texas at Austin, and Analytics and Health Economics, Seton Healthcare Family, Austin, Texas.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH